Literature DB >> 18504121

Micrometastases in thyroid cancer. An important finding?

Isaac M Cranshaw1, Bruno Carnaille.   

Abstract

Differentiated thyroid cancer is a cancer with a good prognosis but the presence of lymph node metastases is associated with increased rates of loco-regional recurrence and in some reports decreased survival. This has led to an increased interest in the lymph node status with guidelines calling for routine central node dissection and increased interest in lateral compartment node sampling and sentinel node biopsy. We know from studies in regions where routine central and ipsilateral node dissection is the preferred surgical management of differentiated thyroid cancer that lymph node metastases are present in the majority of cases and that many of these are micrometastatic deposits. However, where routine node dissection is not performed recurrence rates are relatively low suggesting that not all micrometastatic disease progresses to a loco-regional recurrence or that the majority of disease is mopped up by adjuvant radioactive iodine. This review examines the available evidence for the significance of micrometastatic disease in differentiated thyroid cancer and suggests that it is probably of little clinical significance and does not warrant further aggressive surgical intervention. We would expect a conservative surgical approach combined with adjuvant radioactive iodine to lead to durable disease control.

Entities:  

Mesh:

Year:  2008        PMID: 18504121     DOI: 10.1016/j.suronc.2008.04.005

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  31 in total

1.  Macrometastasis in Papillary Thyroid Cancer Patients is Associated with Higher Recurrence in Lateral Neck Nodes.

Authors:  Soo Young Kim; Bup-Woo Kim; Ju Yeon Pyo; Soon Won Hong; Hang-Seok Chang; Cheong Soo Park
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

2.  Role of RAI in the management of incidental N1a disease in papillary thyroid cancer.

Authors:  Laura Y Wang; Frank L Palmer; Jocelyn C Migliacci; Iain J Nixon; Ashok R Shaha; Jatin P Shah; Robert Michael Tuttle; Snehal G Patel; Ian Ganly
Journal:  Clin Endocrinol (Oxf)       Date:  2015-07-03       Impact factor: 3.478

Review 3.  Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review.

Authors:  Elisabeth Mamelle; Isabelle Borget; Sophie Leboulleux; Haïtham Mirghani; Carlos Suárez; Phillip K Pellitteri; Ashok R Shaha; Marc Hamoir; K Thomas Robbins; Avi Khafif; Juan P Rodrigo; Carl E Silver; Alessandra Rinaldo; Alfio Ferlito; Dana M Hartl
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-11       Impact factor: 2.503

Review 4.  Surgical approach to level VI in papillary thyroid carcinoma: an overview.

Authors:  Carmela De Crea; Marco Raffaelli; Luca Sessa; Celestino Pio Lombardi; Rocco Bellantone
Journal:  Updates Surg       Date:  2017-06-13

5.  Can intraoperative frozen section influence the extension of central neck dissection in cN0 papillary thyroid carcinoma?

Authors:  Marco Raffaelli; Carmela De Crea; Luca Sessa; Piero Giustacchini; Rocco Bellantone; Celestino Pio Lombardi
Journal:  Langenbecks Arch Surg       Date:  2012-12-04       Impact factor: 3.445

6.  Pathologic features of metastatic lymph nodes identified from prophylactic central neck dissection in patients with papillary thyroid carcinoma.

Authors:  Hyoung Shin Lee; Chanwoo Park; Sung Won Kim; Woong Jae Noh; Soo Jin Lim; Bong Kwon Chun; Beom Su Kim; Jong Chul Hong; Kang Dae Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-12       Impact factor: 2.503

7.  Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.

Authors:  Julio Ricarte-Filho; Ian Ganly; Michael Rivera; Nora Katabi; Weimin Fu; Ashok Shaha; R Michael Tuttle; James A Fagin; Ronald Ghossein
Journal:  Thyroid       Date:  2012-04-03       Impact factor: 6.568

8.  Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastases.

Authors:  Fabián Pitoia; Erika Abelleira; Graciela Cross
Journal:  Eur Thyroid J       Date:  2014-12-06

9.  Role of sentinel node in differentiated thyroid cancer: a prospective study comparing patent blue injection technique, lymphoscintigraphy and the combined technique.

Authors:  R Gelmini; M Campanelli; F Cabry; A Franceschetto; G Ceresini; L Ruffini; A Zaccaroni; P Del Rio
Journal:  J Endocrinol Invest       Date:  2017-08-31       Impact factor: 4.256

10.  Is thymectomy worthwhile in central lymph node dissection for differentiated thyroid cancer?

Authors:  Ziad El Khatib; Julie Lamblin; Sebastien Aubert; Laurent Arnalsteen; Emmanuelle Leteurtre; Robert Caiazzo; Francois Pattou; Bruno Carnaille
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.